Melanoma Clinical Trials
Back to Oncology/Cancer Clinical Trials Main Page
CPMC Cancer Services
| Principal Investigator/Contact Information | Protocol Title | Patient Population | Recruitment Period |
|---|---|---|---|
| Principal Investigator: David Minor, MD Contact: Zeena Salman 415-600-1654 | A Phase II Study of Sunitinib Therapy for Patients with Metastatic Melanoma and KIT Gene Aberrations (Sutent-Kit) | Subjects with Metastatic Melanoma and KIT Gene Aberrations | Open |
| Principal Investigator: David Minor, MD Contact: Ron Frianeza 415-600-3027 | Adjuvant immunotherapy with anti_CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III Melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group. BMS 184-029 | Subjects who have advanced stage III melanoma | Open |
| Principal Investigator: David Minor, MD Contact: Ron Frianeza 415-600-3027 | A Multicenter Treatment Protocol for Compassionate Use of Ipilimumab Monotherapy in Subjects with Unresectable Stage III or Stage IV Melanoma. BMS045 Visit the Compassionate Use of Ipilimumab Monotherapy study on ClinicalTrials.gov. | Subjects who have advanced stage III or IV melanoma that cannot be treated with surgery | Open |
| Principal Investigator: David Minor, MD Contact: Ron Frianeza 415-600-3027 | A Multicenter, Open-Label, Phase II Study of Ipilimumab (MDX-010) Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab. BMS025 | Subjects who have advanced melanoma and have received a drug called ipilimumab in an earlier study | Closed to Enrollment |
| Principal Investigator: David Minor, MD Contact: Zeena Salman 415-600-1654 | A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination with Temozolomide Versus Temozolomide Alone in Subjects with Metastatic Melanoma. Abbott: M10-440 Visit the Temozolomide study on ClinicalTrials.gov. | Subjects with Melanoma with cutaneous (relating to the skin) orgins | Closed to Enrollment |
updated: 1/27/10
Back to top